Leerink Partners Cuts Price target on Diplomat Pharmacy (DPLO) Following Weak EPS Guide
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Diplomat Announces 4th Quarter and 2015 Year End Financial Results; Provides Initial 2016 Guidance
February 29, 2016 4:15 PM ESTFLINT, Mich., Feb. 29, 2016 /PRNewswire/ --Â Click here for additional information on the earnings results.Â
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter and year ended December 31, 2015. All comparisons, unless otherwise noted, are to the quarter or year ended December 31, 2014.
Fourth Quarter 2015 Highlights include:
Revenue of $987 million, an increase of 61% or $375... More